EditorialMethodology
Tumor Pretargeting: Almost the Bottom Line
David A. Goodwin
Journal of Nuclear Medicine May 1995, 36 (5) 876-879;
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Tumor Pretargeting: Almost the Bottom Line
David A. Goodwin
Journal of Nuclear Medicine May 1995, 36 (5) 876-879;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy
- Successful Radiotherapy of Tumor in Pretargeted Mice by 188Re-Radiolabeled Phosphorodiamidate Morpholino Oligomer, a Synthetic DNA Analogue.
- Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- Tumor Pretargeting in Mice Using 99mTc-Labeled Morpholino, a DNA Analog
- Biodistribution and Dosimetry of Pretargeted Monoclonal Antibody 2D12.5 and Y-Janus-DOTA in BALB/c Mice with KHJJ Mouse Adenocarcinoma
- Tumor Pretargeting with Avidin Improves the Therapeutic Index of Biotinylated Tumor Necrosis Factor {{alpha}} in Mouse Models